Taysha Gene Therapies (Nasdaq: TSHA) will report second quarter 2026 financial results and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time. The live and archived webcast will be accessible via the Events and Presentations page of Taysha’s investor relations website.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The two prior tag-specific scheduling notices produced reactions of -0.48% and +2.1%, framing this A...
Analysis
The two prior tag-specific scheduling notices produced reactions of -0.48% and +2.1%, framing this August 11 date as a recurring calendar event rather than a results disclosure. The financial update remains the key information point; insider net selling is a risk.
Announced full-year results release and webcast timing for March 19.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The two tag-specific prior earnings-date notices produced mixed reactions, ranging from -0.48% to +2.1%.
Key Terms
aav, cns, monogenic diseases, aav9 capsid
4 terms
aavmedical
"focused on advancing adeno-associated virus (AAV)-based gene therapies"
AAV is a small, generally harmless virus repurposed by researchers as a delivery vehicle to insert therapeutic genes into human cells; think of it as a postal service that carries corrective DNA to specific tissues. Investors pay attention because AAV-based treatments can offer durable, potentially one-time cures that command high prices, but they also carry development, manufacturing and regulatory risks that can sharply influence a biotech company’s value.
cnsmedical
"severe monogenic diseases of the central nervous system (CNS)"
CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.
monogenic diseasesmedical
"gene therapies for severe monogenic diseases of the central nervous system"
A monogenic disease is a medical condition caused by a harmful change in a single gene, where that single faulty instruction is enough to produce symptoms. For investors, these diseases matter because their clear genetic cause can make it easier for drug developers to design targeted therapies, diagnostics, or gene therapies, creating distinct clinical pathways, regulatory considerations, and potentially more predictable commercial opportunities—like fixing one broken line of code in a program.
aav9 capsidtechnical
"a clinically and commercially proven AAV9 capsid"
AAV9 capsid is the protein shell of adeno-associated virus serotype 9 used to package and deliver genetic material in gene therapy. The capsid controls which tissues the vector naturally targets, how the immune system recognizes it, and how easy it is to manufacture and scale. For investors, those properties affect a therapy’s potential market reach, development complexity, safety profile, and regulatory considerations—like choosing the right delivery truck for a specific cargo and route.
DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2026, and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time.
Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at ir.tayshagtx.com. An archived replay of the webcast will be available on the Company’s website.
About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
Company Contact: Hayleigh Collins Senior Director, Corporate Communications and Investor Relations Taysha Gene Therapies, Inc. hcollins@tayshagtx.com
When will Taysha Gene Therapies (TSHA) release its Q2 2026 financial results?
Taysha Gene Therapies plans to release its Q2 2026 financial results on Tuesday, August 11, 2026. According to Taysha, the announcement will be followed by a corporate update conference call and webcast the same day.
What time is Taysha Gene Therapies' Q2 2026 earnings conference call for TSHA shareholders?
The Q2 2026 conference call and webcast for Taysha Gene Therapies is scheduled for 4:30 PM Eastern Time on August 11, 2026. According to Taysha, the event will include a financial update and corporate overview.
How can investors access the Taysha Gene Therapies (TSHA) Q2 2026 webcast on August 11, 2026?
Investors can access the live Q2 2026 webcast from the Events and Presentations page of Taysha’s investor relations website at ir.tayshagtx.com. According to Taysha, the webcast will be available in real time during the call.
Will a replay of the Taysha Gene Therapies (TSHA) Q2 2026 earnings call be available?
Yes, an archived replay of the Q2 2026 webcast will be available on the company’s website. According to Taysha, the replay can be accessed after the live conference call concludes via the Events and Presentations page.
What does Taysha Gene Therapies focus on in its clinical-stage pipeline for TSHA investors?
Taysha Gene Therapies focuses on AAV-based gene therapies for severe monogenic CNS diseases. According to Taysha, its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder without approved disease-modifying therapies.
What is TSHA-102, the lead program of Taysha Gene Therapies (TSHA)?
TSHA-102 is Taysha Gene Therapies’ lead clinical gene therapy program for Rett syndrome. According to Taysha, it targets the genetic root cause of this rare neurodevelopmental disorder, which currently lacks approved disease-modifying treatments.
